Neuromorphic Computing Stack
Discover companies pioneering brain-inspired computing technology that's reshaping AI hardware. These carefully selected stocks represent innovators across the semiconductor ecosystem, all focused on creating more efficient, powerful chips to meet the growing demands of artificial intelligence.
Your Basket's Financial Footprint
This basket's total market capitalisation is 7,510,835.189100002 and is heavily anchored by a few large-cap stocks, giving it a generally stable profile.
- Large-cap dominance generally implies lower volatility and closer tracking of broad market moves, though risk remains.
- Suitability as a core holding rather than a speculative, high-growth wager; use for diversified, long-term exposure.
- Expect steady, long-term value accumulation rather than explosive short-term gains; growth is more gradual and probable.
NVDA: $4.40T
INTC: $178.03B
TSM: $1.23T
- Other
About This Group of Stocks
Our Expert Thinking
The future of AI requires a fundamental shift in hardware. Traditional computing can't sustainably support AI's massive energy demands. Neuromorphic technology addresses this by mimicking the brain's efficiency, creating a powerful investment opportunity as companies race to build more sustainable AI infrastructure.
What You Need to Know
This collection represents the entire neuromorphic value chain—from chip designers and manufacturers to equipment makers and memory providers. The portfolio balances established tech giants with specialized players, capturing both immediate market leaders and companies developing tomorrow's breakthrough technologies.
Why These Stocks
These companies were selected based on their critical roles in developing or enabling neuromorphic computing. Each represents an essential piece of the ecosystem needed to advance brain-inspired technology, from research pioneers like Intel with its Loihi chip to foundries like TSMC that manufacture these complex processors.
Why You'll Want to Watch These Stocks
The AI Power Crisis Solution
As AI models grow exponentially larger, their energy demands become unsustainable. These companies are racing to solve this critical bottleneck with brain-inspired chips that could deliver 1000x greater efficiency.
Early in a Massive Shift
Neuromorphic computing isn't just another tech trend—it's a fundamental redesign of computer architecture that hasn't changed in decades. You're looking at the companies leading a once-in-a-generation hardware revolution.
The Complete Value Chain
Most tech investments focus on a single company or sector. This carefully curated group gives you exposure to the entire neuromorphic ecosystem—from chip designers and foundries to equipment makers and memory providers.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Tech Stocks (AI Valuation Reset) Present Potential Entry
Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.
Walmart Succession Plan Explained | Market Effects
Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.
Biotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.